Aurinia Pharmaceuticals
IPOChanging the Trajectory of Autoimmune Diseases
- Employees
- 51–200
- Business Model
- B2B
- Website
- auriniapharma.com
- Type
- Public
About
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on treating autoimmune diseases with high unmet medical needs. Its lead commercial product, LUPKYNIS (voclosporin), is approved for lupus nephritis. The company is advancing a pipeline including aritinercept for additional autoimmune indications.
Summary
Aurinia Pharmaceuticals is a Biotech company.
Tech & App Stack
3 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jan 2001
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.